Skip to NavigationSkip to content

BMS' Opdivo fails to improve overall survival in small-cell lung cancer

Published on 15/10/18 at 10:59am

Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, failing to significantly improve overall survival (OS) in patients who had relapsed following platinum-based chemotherapy.

The trial examined the drug’s efficacy in two randomised groups, with one receiving Opdivo and the other using either topotecan or amrubicin. The primary endpoint was OS, while secondary endpoints included progression-free survival and objective response rates.

Despite being found to not provide sufficient OS benefit versus chemotherapy alone in this indication, the study found the safety profile of the PD-1 inhibitor to be consistent with previous findings.

“Small cell lung cancer is a highly aggressive disease in which significant unmet need remains,” commented Dr Sabine Maier, Development Lead, Thoracic Cancers, Bristol-Myers Squibb. “We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer. We thank the patients, their families, and the physicians involved in the CheckMate -331 study.”

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches